You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFenoprofen
Accession NumberDB00573  (APRD00970)
TypeSmall Molecule
GroupsApproved
DescriptionAn anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. [PubChem]
Structure
Thumb
Synonyms
(+-)-2-(3-Phenoxyphenyl)propionic acid
(+/-)-fenoprofen
(+/-)-m-phenoxyhydratropic acid
2-(3-phenoxyphenyl)propionic acid
2-(m-phenoxyphenyl)propionic acid
3-phenoxyhydratropic acid
alpha-(m-Phenoxyphenyl)propionic acid
alpha-Methyl-3-phenoxybenzeneacetic acid
DL-2-(3-phenoxyphenyl)propionic acid
Fenoprofen
Fénoprofène
Fenoprofeno
Fenoprofenum
External Identifiers
  • 69323
  • Lilly 53858
  • LILLY-53858
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FenoprofenCapsule400 mg/1OralMedsource Pharmaceuticals2014-07-14Not applicableUs
FenoprofenCapsule400 mg/1Oralbryant ranch prepack2014-07-14Not applicableUs
FenoprofenCapsule400 mg/1OralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
FenoprofenCapsule400 mg/1OralKLE 2, Inc.2014-07-142015-12-29Us
Fenoprofen CalciumCapsule200 mg/1OralBpi Labs Llc2016-07-06Not applicableUs
Fenoprofen CalciumCapsule400 mg/1OralBpi Labs Llc2016-07-06Not applicableUs
Fenoprofen CalciumCapsule400 mg/1OralXspire Pharma2015-08-05Not applicableUs
FenorthoCapsule200 mg/1OralBpi Labs Llc2016-06-14Not applicableUs
FenorthoCapsule400 mg/1OralBpi Labs Llc2016-06-14Not applicableUs
NalfonCapsule400 mg/1OralXspire Pharma2012-08-27Not applicableUs
NalfonCapsule200 mg/1OralXspire Pharma2012-08-27Not applicableUs
NalfonCapsule400 mg/1OralProficient Rx LP2012-08-27Not applicableUs
Nalfon Cap 300mgCapsule300 mgOralEli Lilly Canada Inc1975-12-312002-07-26Canada
Nalfon Tab 600mgTablet600 mgOralEli Lilly Canada Inc1975-12-312002-07-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fenoprofen CalciumTablet, film coated600 mg/1OralMylan Pharmaceuticals Inc.2012-11-14Not applicableUs
Fenoprofen CalciumTablet, film coated600 mg/1OralPd Rx Pharmaceuticals, Inc.2009-11-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FeilinHengshan Pharmaceutical
FenopronTypharm
FepronSheng Chung Tang
KimpronDaewoong
NalgésicSciencex
NonsicHasan
NoprofenPanion & BF
TrandorBiolab
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fenoprofen calcium
53746-45-5
Thumb
  • InChI Key: LZPBLUATTGKZBH-UHFFFAOYSA-L
  • Monoisotopic Mass: 558.1566588
  • Average Mass: 558.64
DBSALT001038
Fenoprofen sodium
34691-31-1
Thumb
  • InChI Key: WVKIYGXHDKTNFO-UHFFFAOYSA-M
  • Monoisotopic Mass: 264.07623856
  • Average Mass: 264.256
DBSALT001848
Categories
UNIIRA33EAC7KY
CAS number29679-58-1
WeightAverage: 242.2699
Monoisotopic: 242.094294314
Chemical FormulaC15H14O3
InChI KeyRDJGLLICXDHJDY-UHFFFAOYSA-N
InChI
InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)
IUPAC Name
2-(3-phenoxyphenyl)propanoic acid
SMILES
CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1
Pharmacology
IndicationFor relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
Structured Indications
PharmacodynamicsFenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect.
Mechanism of actionFenoprofen's exact mode of action is unknown, but it is thought that prostaglandin synthetase inhibition is involved. Fenoprofen has been shown to inhibit prostaglandin synthetase isolated from bovine seminal vesicles.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionRapidly absorbed under fasting conditions, and peak plasma levels of 50 µg/mL are achieved within 2 hours after oral administration of 600 mg doses.
Volume of distributionNot Available
Protein binding99% to albumin.
Metabolism

About 90% of a single oral dose is eliminated within 24 hours as fenoprofen glucuronide and 4'-hydroxyfenoprofen glucuronide, the major urinary metabolites of fenoprofen.

SubstrateEnzymesProduct
Fenoprofen
Not Available
4'-hydroxyfenoprofen glucuronideDetails
Fenoprofen
Not Available
Fenoprofen glucuronideDetails
Route of eliminationNot Available
Half lifePlasma half-life is approximately 3 hours.
ClearanceNot Available
ToxicitySymptoms of overdose appear within several hours and generally involve the gastrointestinal and central nervous systems. They include dyspepsia, nausea, vomiting, abdominal pain, dizziness, headache, ataxia, tinnitus, tremor, drowsiness, and confusion. Hyperpyrexia, tachycardia, hypotension, and acute renal failure may occur rarely following overdose. Respiratory depression and metabolic acidosis have also been reported following overdose with certain NSAIDs.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fenoprofen Action PathwayDrug actionSMP00696
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabFenoprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololFenoprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Aceclofenac.Approved
AcenocoumarolFenoprofen may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinFenoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fenoprofen.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.Approved
AliskirenFenoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololFenoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Fenoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Amcinonide.Approved
AmikacinFenoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideFenoprofen may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinFenoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodFenoprofen may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Anisodamine.Investigational
annamycinFenoprofen may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Antipyrine.Approved
Antithrombin III humanFenoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Fenoprofen may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanFenoprofen may increase the anticoagulant activities of Apixaban.Approved
ApramycinFenoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Apremilast.Approved, Investigational
ArbekacinFenoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinFenoprofen may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanFenoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololFenoprofen may decrease the antihypertensive activities of Arotinolol.Approved
AtenololFenoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenoprofen.Approved
BalsalazideFenoprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminFenoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololFenoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Fenoprofen.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Fenoprofen.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fenoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololFenoprofen may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Betulinic Acid.Investigational
BevantololFenoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Fenoprofen.Approved, Investigational
BisoprololFenoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinFenoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololFenoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bucillamine.Investigational
BucindololFenoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Budesonide.Approved
BufuralolFenoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideFenoprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololFenoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Fenoprofen.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Fenoprofen.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Fenoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololFenoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolFenoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Celecoxib.Approved, Investigational
CeliprololFenoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinFenoprofen may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenoprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenoprofen.Approved
CinoxacinFenoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinFenoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidFenoprofen may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Fenoprofen.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Curcumin.Investigational
CyclosporineFenoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with D-Limonene.Investigational
Dabigatran etexilateFenoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinFenoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidFenoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinFenoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinFenoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Fenoprofen.Approved
DextranFenoprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Fenoprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Fenoprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Fenoprofen may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fenoprofen.Approved, Vet Approved
DicoumarolFenoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fenoprofen.Approved
DihydrostreptomycinFenoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Fenoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Fenoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Fenoprofen.Approved
DoxorubicinFenoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneFenoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Fenoprofen is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ebselen.Investigational
Edetic AcidFenoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanFenoprofen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Fenoprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Fenoprofen.Approved
EnoxacinFenoprofen may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinFenoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Epirizole.Approved
EpirubicinFenoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneFenoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Equilin.Approved
EsmololFenoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Estrone sulfate.Approved
Etacrynic acidFenoprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fenoprofen.Approved, Investigational
Ethyl biscoumacetateFenoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Fenoprofen is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fenbufen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Fenoprofen.Vet Approved
FleroxacinFenoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fenoprofen.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fludrocortisone.Approved
FluindioneFenoprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFenoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Fenoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Fenoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxFenoprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFenoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Fenoprofen.Approved
FramycetinFenoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideFenoprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateFenoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinFenoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinFenoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Fenoprofen.Approved, Withdrawn
GemifloxacinFenoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinFenoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinFenoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AFenoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinFenoprofen may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Fenoprofen is combined with HE3286.Investigational
HeparinFenoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Higenamine.Investigational
HirulogFenoprofen may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Fenoprofen is combined with HMPL-004.Investigational
HydralazineFenoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Fenoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenoprofen.Approved
Hygromycin BFenoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Icatibant.Approved
IdarubicinFenoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxFenoprofen may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Fenoprofen.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenoprofen.Approved
IndenololFenoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Indoprofen.Withdrawn
INNO-206Fenoprofen may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenoprofen.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Istaroxime.Investigational
KanamycinFenoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fenoprofen.Approved
LabetalolFenoprofen may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Fenoprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Leflunomide.Approved, Investigational
LepirudinFenoprofen may increase the anticoagulant activities of Lepirudin.Approved
LevobunololFenoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinFenoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Fenoprofen.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Fenoprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Fenoprofen.Approved
LomefloxacinFenoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fenoprofen.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fenoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Fenoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenoprofen.Approved
ME-609The risk or severity of adverse effects can be increased when Fenoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meloxicam.Approved, Vet Approved
MesalazineFenoprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fenoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololFenoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen.Approved
MetoprololFenoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideFenoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fenoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenoprofen.Approved
MometasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Fenoprofen.Approved
MoxifloxacinFenoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nabumetone.Approved
NadololFenoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinFenoprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatFenoprofen may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naftifine.Approved
Nalidixic AcidFenoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Fenoprofen is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Fenoprofen is combined with NCX 4016.Investigational
NeamineFenoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinFenoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinFenoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nepafenac.Approved
NetilmicinFenoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nitroaspirin.Investigational
NorfloxacinFenoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinFenoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fenoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Olopatadine.Approved
OlsalazineFenoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Fenoprofen.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Orgotein.Vet Approved
OtamixabanFenoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxaprozin.Approved
OxprenololFenoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Parecoxib.Approved
ParomomycinFenoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinFenoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinFenoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololFenoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateFenoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Fenoprofen.Approved
PhenindioneFenoprofen may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonFenoprofen may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fenoprofen.Approved, Investigational
PindololFenoprofen may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinFenoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideFenoprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenoprofen.Approved, Investigational
PlicamycinFenoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Fenoprofen.Approved
PractololFenoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Fenoprofen.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Fenoprofen can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Propacetamol.Approved
PropranololFenoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Fenoprofen.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Fenoprofen.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Fenoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Fenoprofen.Vet Approved
Protein CFenoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanFenoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeFenoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinFenoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Fenoprofen is combined with PTC299.Investigational
PuromycinFenoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenoprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Fenoprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Fenoprofen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenoprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.Experimental, Investigational
ReviparinFenoprofen may increase the anticoagulant activities of Reviparin.Approved
RibostamycinFenoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanFenoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinFenoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Fenoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fenoprofen.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Seratrodast.Approved, Investigational
SisomicinFenoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolFenoprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CFenoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinFenoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinFenoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Fenoprofen.Approved
SpironolactoneFenoprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Fenoprofen is combined with SRT501.Investigational
StreptomycinFenoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinFenoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineFenoprofen may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Sulindac.Approved
SulodexideFenoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Fenoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Suprofen.Approved, Withdrawn
TacrolimusFenoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Fenoprofen.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Fenoprofen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fenoprofen.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenoprofen.Approved, Investigational
TemafloxacinFenoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Fenoprofen.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fenoprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tiludronate.Approved, Vet Approved
TimololFenoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tixocortol.Approved
TobramycinFenoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenoprofen.Approved
TorasemideFenoprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Fenoprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Fenoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneFenoprofen may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenoprofen.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Trisalicylate-choline.Approved
TrovafloxacinFenoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Fenoprofen.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinFenoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenoprofen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Fenoprofen.Approved
WarfarinFenoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranFenoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Fenoprofen may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zileuton.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zomepirac.Withdrawn
ZorubicinFenoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Marshall, W.S.; U.S. Patent 3,600,437; August 17, 1971; assigned to Eli Lilly and Company.

General ReferencesNot Available
External Links
ATC CodesM01AE04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (141 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.8373
Caco-2 permeable+0.8876
P-glycoprotein substrateNon-substrate0.6587
P-glycoprotein inhibitor INon-inhibitor0.8897
P-glycoprotein inhibitor IINon-inhibitor0.9357
Renal organic cation transporterNon-inhibitor0.8521
CYP450 2C9 substrateNon-substrate0.6883
CYP450 2D6 substrateNon-substrate0.9354
CYP450 3A4 substrateNon-substrate0.6779
CYP450 1A2 substrateInhibitor0.5871
CYP450 2C9 inhibitorNon-inhibitor0.8382
CYP450 2D6 inhibitorNon-inhibitor0.9769
CYP450 2C19 inhibitorNon-inhibitor0.7675
CYP450 3A4 inhibitorNon-inhibitor0.938
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8169
Ames testNon AMES toxic0.9558
CarcinogenicityNon-carcinogens0.7885
BiodegradationReady biodegradable0.5267
Rat acute toxicity1.9985 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9517
hERG inhibition (predictor II)Non-inhibitor0.9414
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • American therapeutics inc
  • Halsey drug co inc
  • Par pharmaceutical inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Pedinol pharmacal inc
  • Actavis elizabeth llc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Usl pharma inc
  • Dista products co div eli lilly and co
Packagers
Dosage forms
FormRouteStrength
CapsuleOral400 mg/1
Tablet, film coatedOral600 mg/1
CapsuleOral200 mg/1
CapsuleOral300 mg
TabletOral600 mg
Prices
Unit descriptionCostUnit
Fenoprofen calcium powder1.59USD g
Fenoprofen Calcium 600 mg tablet1.01USD tablet
Nalfon 200 mg capsule0.91USD capsule
Fenoprofen 600 mg tablet0.88USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168-171Marshall, W.S.; U.S. Patent 3,600,437; August 17, 1971; assigned to Eli Lilly and Company.
water solubilitySlight (calcium salt)Not Available
logP3.1Not Available
pKa4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0811 mg/mLALOGPS
logP3.87ALOGPS
logP3.65ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)3.96ChemAxon
pKa (Strongest Basic)-8.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.18 m3·mol-1ChemAxon
Polarizability25.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • 2-phenylpropanoic-acid
  • Diaryl ether
  • Phenylacetate
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36. [PubMed:17050798 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Poggi JC, Barissa GR, Donadi EA, Foss MC, Cunha FQ, Lanchote VL, dos Reis ML: Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol. 2006 Nov;46(11):1328-36. [PubMed:17050798 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23